Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lipid hypothesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Lipid hypothesis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-000981-12 Sponsor Protocol Number: ALIROCKS_05MAR2018_V3 Start Date*: 2018-05-11
    Sponsor Name:Medical University of Graz
    Full Title: A PILOT STUDY INVESTIGATING THE EFFECTS OF LIPID-THERAPY INTENSIFICATION WITH ALIROCUMAB ON ENDOTHELIAL FUNCTION, CAROTID ARTERIES, LIPOPROTEIN PARTICLE SUBFRACTIONS, INFLAMMATION AND POST-PRANDIAL...
    Medical condition: Primary Hypercholesterolemia in secondary prevention after an acute atherosclerotic, ischaemic cardiovascular event for patients with diagnostically confirmed coronary heart disease and / or periph...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003827-37 Sponsor Protocol Number: 20110109 Start Date*: 2012-01-06
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-term Tolerability and Durable Efficacy of AMG 145 on LDL-C in Hyperlipidemic Subjects
    Medical condition: Hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: CZ (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-009921-28 Sponsor Protocol Number: PLOTINA Start Date*: 2010-05-15
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: The Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial
    Medical condition: Breast cancer chemoprevention
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004218-34 Sponsor Protocol Number: NIFLO Start Date*: 2006-04-27
    Sponsor Name:Department of Cardiology, UK Aachen
    Full Title: Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins
    Medical condition: coronary artery disease and lipid disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013157-15 Sponsor Protocol Number: 1218.74 Start Date*: 2010-10-14
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...
    Medical condition: Patients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV events prior to informed consent can be enrolled in the study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000072461 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) IE (Completed) FI (Completed) SE (Completed) GB (Completed) SK (Completed) IT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-006208-21 Sponsor Protocol Number: ELKE-2006 Start Date*: 2006-10-23
    Sponsor Name:Department of Dermatology, University of Kiel
    Full Title: Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and diff...
    Medical condition: Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003611-62 Sponsor Protocol Number: LIB003-003 Start Date*: 2020-03-20
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 with Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy.
    Medical condition: Homozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005006-35 Sponsor Protocol Number: RM-493-022 Start Date*: 2018-05-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 recepto...
    Medical condition: Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genet...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005047-28 Sponsor Protocol Number: CS0011-A-U301 Start Date*: 2007-03-23
    Sponsor Name:DAIICHI SANKYO PHARMA DEVELOPMENT
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS
    Medical condition: The current study will support an indication for rivoglitazone as oral monotherapy to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with diet and exer...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) LV (Completed) SK (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001007-12 Sponsor Protocol Number: MK-0524B-143 Start Date*: 2011-07-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Pati...
    Medical condition: Primary Hypercholesterolemia & Mixed Dyslipdemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) NL (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) NO (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002627-40 Sponsor Protocol Number: P02579 Start Date*: 2005-06-15
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia
    Medical condition: Adolescent (age >=10 and <=17 years) subjects with Heterozygous Familial Hypercholesterolemia (HeFH).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057099 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) DE (Completed) IT (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002125-32 Sponsor Protocol Number: 308683 Start Date*: 2005-12-22
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A multicenter, open, randomized, parallel-group comparison to assess the safety and efficacy of the oral contraceptive SH T 00186 D (0.02 mg ethinylestradiol as betadex clathrate and 3 mg drospiren...
    Medical condition: healthy volunteers requesting oral contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004681-15 Sponsor Protocol Number: KIMCL_TS_2011-09 Start Date*: 2011-11-09
    Sponsor Name:Medizinische Universität Graz
    Full Title: Effects of the activation of peroxisome proliferator-activated receptors in patients with primary biliary cirrhosis
    Medical condition: Up to 67% of PBC patients have an incomplete biochemical response to UDCA and remain at increased risk for progression to cirrhosis and liver-related death. In this study we will prospectively exam...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000610-10 Sponsor Protocol Number: RivAsA Start Date*: 2020-01-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with s...
    Medical condition: type 2 diabetic patients with stable peripheral or carotid artery disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10067825 Peripheral arterial disease LLT
    21.0 10027433 - Metabolism and nutrition disorders 10053247 Insulin-requiring type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000499-32 Sponsor Protocol Number: FSJD-ABELNEB-2010 Start Date*: 2011-09-29
    Sponsor Name:FUNDACIÓ SANT JOAN DE DEU
    Full Title: A PHASE II CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF AMPHOTERICIN B LIPID COMPLEX (ABELCET®) FOR THE PROPHYLAXIS OF INVASIVE PULMONARY ASPERGILLOSIS DURING PROLONGED NEUTROPENIA IN ...
    Medical condition: Invasive pulmonary aspergillosis in patients with acute myeloblastic or lymphoblastic leukaemia.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023939-42 Sponsor Protocol Number: MK-0524B-118 Start Date*: 2011-05-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with P...
    Medical condition: Primary Hypercholesterolemia & Mixed Dyslipdemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) BG (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005550-18 Sponsor Protocol Number: 1439A-024 Start Date*: 2015-08-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) DK (Completed) BE (Completed) IT (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013420-23 Sponsor Protocol Number: F1J-US-HMGO Start Date*: 2009-11-09
    Sponsor Name:Eli Lilly and Company
    Full Title: Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects with Major Depressive Disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020464-38 Sponsor Protocol Number: PRENU Start Date*: 2010-06-08
    Sponsor Name:University of Oslo
    Full Title: Nutrition, growth and development among very preterm infants
    Medical condition: The main purpose of this study is to evaluate the effect of increased supply of energy, protein, vitamin A and the long chain polyunsaturated fatty acids DHA and AA to Very Low Birth Weight Infants...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003575-11 Sponsor Protocol Number: VitaminD&TT Start Date*: 2013-03-05
    Sponsor Name:Medizinische Universität Graz, Innere Medizin
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men
    Medical condition: Male hypogonadism (total testosterone <3ng/ml)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10000193 Male sex hormone abnormalities HLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 03:54:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA